100% Lab-Tested
Free Shipping on Orders $50+
Card Payments Accepted

Ibogaine — Compound Profile

by amama in Substances

Ibogaine

2D structure of Ibogaine (C20H26N2O) — source: PubChem CID 197060
2D structure of Ibogaine (C20H26N2O) — source: PubChem CID 197060

Chemistry

  • CID: 197060 · PubChem
  • Formula: C20H26N2O
  • Molecular weight: 310.4 g/mol
  • IUPAC: (1R,15R,17S,18S)-17-ethyl-7-methoxy-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4(9),5,7-tetraene
  • CAS: 83-74-9

Family & pharmacology

Family: Indole alkaloid (ibogamine-type)

Pharmacological class: NMDA receptor antagonist; kappa-opioid receptor agonist; sigma-2 receptor agonist; serotonin transporter inhibitor (SERT); nicotinic acetylcholine receptor antagonist. Preclinical data also indicate upregulation of BDNF (brain-derived neurotrophic factor), which may underlie reported neuroplastic effects in animal models.

Natural source: Ibogaine is the principal psychoactive alkaloid in the root bark of Tabernanthe iboga, a perennial understory shrub native to the rainforests of Gabon, Cameroon, and the Republic of Congo. The root bark contains a complex of 12 or more iboga alkaloids; ibogaine typically constitutes 10–20 % of total alkaloid content.

Historical context

Ibogaine was first isolated in 1901 by French pharmacologists Dybowski and Landrin from Tabernanthe iboga, two years after iboga root bark was exhibited at the Paris Exposition. Its full chemical structure was determined in 1958, followed by the first total synthesis by Büchi et al. (J. Am. Chem. Soc. 1958). Western pharmaceutical interest peaked in the 1960s when it was briefly marketed in France as Lambarène — a stimulant tonic — before being withdrawn from the market.

Modern addiction-interruption research traces to self-experimenter Howard Lotsof, who in 1962 observed that a single session appeared to interrupt his heroin use and filed the first treatment patents in the 1980s. Alper et al. (Alkaloids 1999, PMID 10332749) published a systematic review of 33 cases, establishing ibogaine's profile in the clinical literature.

Traditional use — Bwiti ceremony

  • Central to the Bwiti initiation rite of the Mitsogo and Fang peoples of Gabon and Cameroon, where large doses of root bark are consumed over multi-day initiation ceremonies
  • Considered a sacrament that enables contact with ancestral spirits; the full initiatory dose is taken once in a lifetime in traditional contexts
  • Smaller doses are used in ongoing Bwiti ritual practice, notably as a collective stimulant during all-night ceremonies (ngoze)
  • Listed as part of the UNESCO-recognized Bwiti intangible cultural heritage of Gabon (2008)

Modern research context

Contemporary clinical interest centres on ibogaine's reported ability to reduce opioid withdrawal symptoms and craving in a single session. Noller et al. (Subst Abuse 2018, PMID 29869598) found significant reductions in opioid use scores 12 months after treatment in a New Zealand open-label study (n=14). A Stanford retrospective (Nat Med 2023, PMID 36905680) of military veterans reported substantial reductions in PTSD, depression, and anxiety scales.

Mechanistically, the multi-receptor profile — including BDNF upregulation, NMDA antagonism, and kappa-opioid activity — distinguishes ibogaine from single-target pharmacotherapies. It is actively investigated at MAPS, NYU, and the Universidade Federal Fluminense.

Safety

Ibogaine carries a well-documented cardiac risk: QT interval prolongation that can trigger fatal ventricular arrhythmia (Torsades de Pointes). Litjens & Brunt (Regul Toxicol Pharmacol 2016, PMID 26284997) reviewed 19 ibogaine-related fatalities; most involved pre-existing cardiac conditions or concomitant substances. Medical screening (ECG, electrolytes) and cardiac monitoring during administration are considered standard of care in clinical research settings. Ibogaine is not suitable for self-administration.

Legal status in Germany

Ibogaine is not listed in the Narcotics Act (BtMG, Anlagen I–III) or the New Psychoactive Substances Act (NpSG) as of 2026. Possession and purchase of the compound are not prohibited under substance law. However, ibogaine has no medicinal approval (Arzneimittelgesetz / AMG), meaning it cannot be prescribed or administered therapeutically by healthcare providers in Germany. The distinction between legal possession and unlicensed medical use is critical. See the full analysis in Iboga Legal Status in Germany & Europe 2026.

Related content

Tags: compound-profile iboga ibogaine indole-alkaloid
Previous Post Next Post

Related Posts

3,4-EtMC (Phorium): Scientific Reference Guide to the Research Chemical 2026

Compliance For research use only. Not for human consumption. Sold only to adults for analytical, forensic, or scientific purposes. TL;DR — 3,4-EtMC at a Glance 3,4-EtMC, listed at amama under the name Phorium, is a synthetic research chemical of the cathinone class with structural relation to Methylon (β-keto-MDMA). This article summarises the current state of knowledge for analytical and scientific purposes — not as a guide to use. Cathinone / MDMA-related empathogen Phorium 3,4-EtMC Material: 100 mg/ml Class: Cathinone / MDMA-related empathogen Structural analog of: MDMA / Methylon View Phorium (3,4-EtMC) as research material → Sold strictly for research purposes. Not for human consumption. Substance class: β-Ketocathinone; structurally assigned to the empathogen pharmacophore (3,4-methylenedioxy scaffold), analogous to Methylon Structural classification: Cathinone scaffold rather than phenethylamine scaffold as in MDMA; the β-keto group fundamentally distinguishes 3,4-EtMC from MDMA Legal status DE (as of May 2026): Not listed by name in the BtMG; NpSG substance-group assessment legally open and requiring case-by-case examination — legal grey area Preclinical data situation: Very limited in peer-reviewed literature; pharmacological hypotheses rely predominantly on structural analogy to Methylon and other β-ketocathinones Known risks: Insufficiently characterised; safety profile is not based on controlled clinical studies — substantial knowledge gaps exist Online designation "Legal MDMA": Circulates in the research chemical community; amama explicitly distances itself from this misleading framing amama position: Phorium (3,4-EtMC) is offered exclusively as analytical reference material for research, analytical and forensic purposes — not for human consumption What is 3,4-EtMC? Chemical Identity and Nomenclature 3,4-EtMC is an abbreviation used in the research chemical community for a compound whose full systematic name and exact structure have not yet been uniformly standardised in the published research literature. This is characteristic of very new synthetic compounds that circulate primarily through grey markets and whose scientific characterisation is still in its early stages. The abbreviation "EtMC" suggests an N-ethyl-substituted methcathinone derivative with a 3,4-substituent pattern — typically a 3,4-methylenedioxybenzyl group, as also found in Methylon (β-keto-MDMA, 3,4-methylenedioxy-N-methylcathinone). Some sources in the community interpret "3,4-EtMC" as a variant or isomer with differing N-alkylation (N-ethyl instead of N-methyl), which would structurally distinguish it from Methylon. The exact IUPAC nomenclature is not consolidated in the citable literature and should always be confirmed in the analytical context by spectroscopic verification (NMR, HRMS) of the respective material. Structural key features (hypothetical, from community descriptions): Scaffold: β-Ketocathinone (cathinone class) Aromatic substitution: 3,4-position, presumably methylenedioxyphenyl group (analogous to Methylon) N-substitution: Varies depending on source interpretation; "EtMC" suggests N-ethyl substitution Molecular formula: Not published-verified; structurally analogous to Methylon (C₁₁H₁₃NO₃) with possible N-ethyl modification (hypothetically C₁₂H₁₅NO₃) CAS number: No verified CAS number traceable in international databases (as of May 2026); analytical work should characterise the material itself Structural Comparison: Cathinone vs. Phenethylamine Scaffold The decisive structural difference from MDMA — and a point of material relevance to researchers and regulatory authorities — lies in the β-keto substituent: cathinones such as 3,4-EtMC carry a keto function at the β-position of the side chain, which renders the molecule more polar compared to pure phenethylamines (such as MDMA) and is hypothesised to influence pharmacological properties such as lipophilicity, blood–brain barrier penetration and receptor kinetics. This is a pharmacologically relevant modification, not merely a formal distinction. PubChem reference for structurally analogous compounds: Methylon (Methylon / β-keto-MDMA): PubChem CID 45789647 Cathinone base structure: PubChem CID 62258 Since no verified PubChem entry exists for 3,4-EtMC itself, these CIDs serve as structural reference points for analytical research work. Pharmacology: What Does Preclinical Research Say? Important note: Direct pharmacological data on 3,4-EtMC from peer-reviewed studies are, according to the current state of research (May 2026), absent or only marginally present in the scientific literature. The following pharmacological classification is based exclusively on structural analogy to related, better-characterised compounds — in particular Methylon and other 3,4-methylenedioxy-β-ketocathinones. Any direct extrapolation to 3,4-EtMC is speculative and scientifically unsubstantiated. Hypothetical Pharmacological Profile (from Structural Analogy) For β-ketocathinones of the 3,4-methylenedioxy class, preclinical studies — predominantly on Methylon — suggest the following mechanisms, which are considered research hypotheses for structurally related compounds but cannot be directly extrapolated to 3,4-EtMC: Monoamine transporter interaction: Preclinical in vitro studies on Methylon suggest inhibition of monoamine reuptake transporters (DAT, NET, SERT), as described for the catecholamine and serotonin class. Research data suggest that 3,4-methylenedioxy-β-ketocathinones could act as substrates or inhibitors of the monoamine transporters on the basis of their structure — however, the relative selectivity for DAT vs. SERT is variable and pharmacologically significantly different with minor structural modifications (such as N-ethylation vs. N-methylation). Serotonergic component: Structural analogues with 3,4-methylenedioxy substitution showed indications of serotonergic activity in animal models (rats, mice). Whether 3,4-EtMC exhibits comparable affinities is not substantiated by direct studies and is hypothesised exclusively from structural relatedness. 5-HT2A receptor: Primary 5-HT2A affinities are not characteristic of pure cathinones of the β-keto class; serotonergic effects in models are explained more by transporter substrates than by direct receptor binding. No data are available on this for 3,4-EtMC. Pharmacokinetics (speculative / from structural analogy) For Methylon, the following parameters have been described in preclinical and forensic-toxicological studies, serving as a rough orientation for the structural class — not as a statement about 3,4-EtMC: Metabolism: β-Ketocathinones are typically metabolised via CYP2D6, CYP3A4 and MAO-A/B; N-demethylation and reduction of the keto group to the corresponding alcohols are documented degradation pathways for the class Half-life: Relatively short elimination half-lives are described for Methylon in forensic case reports; corresponding data for 3,4-EtMC are completely absent Prodrug character: No indication of a prodrug mechanism for this substance class; direct activity is hypothesised Consequence for research: The absence of direct pharmacokinetic data makes 3,4-EtMC a substantial knowledge gap in cathinone pharmacology — which makes the substance particularly interesting for analytical and forensic research work, but renders it scientifically unacceptably uninformed for any practical application in humans. 3,4-EtMC Compared to MDMA and Methylon The following table serves scientific classification and explicitly not the comparison of application profiles. Structural similarity does not imply equivalence of effect — minor molecular modifications can dramatically alter the toxicity profile, duration of action, transporter selectivity and side-effect spectrum. Property 3,4-EtMC Methylon (β-keto-MDMA) MDMA Substance class β-Ketocathinone β-Ketocathinone Phenethylamine / Entactogen β-Keto group Yes (cathinone scaffold) Yes No N-substituent N-Ethyl (hypothetical) N-Methyl N-Methyl 3,4-substitution Methylenedioxy (hypothetical) Methylenedioxy Methylenedioxy Legal status DE Not in BtMG; NpSG assessment open (grey area) NpSG schedule (listed) BtMG Schedule I (illegal) Legal status EU Varies by member state; EMCDDA monitoring Various member states: prohibited Controlled everywhere Research depth Very limited / barely peer-reviewed Moderate (forensic literature) Extensive (clinical) Clinical studies None known No controlled clinical studies Yes (e.g. MAPS PTSD programme) Known risks Largely uncharacterised Case reports; serotonergic risks Extensively documented Neurotoxicity data None Animal models: limited data Animal studies: neurotoxic potential PubChem CID Not available (as of 05/2026) CID 45789647 CID 1615 Critical contextualisation: The structural similarity between 3,4-EtMC, Methylon and MDMA gives rise to pharmacological hypotheses, not certainties. In particular, N-ethylation — insofar as applicable to 3,4-EtMC — can, compared to N-methylation in Methylon, lead to differing transporter affinities, altered lipophilicity and consequently an altered pharmacological profile. This is well documented in the β-ketocathinone literature for comparable N-alkyl modifications (e.g. MDPV vs. related structures). Reported Effects in Online Forums — Distanced Documentation ⚠️ Methodological limitation: Experiential reports from online forums (Erowid, Reddit, Bluelight) are anecdotal, uncontrolled, not peer-reviewed and do not constitute scientific evidence for effects, safety or pharmacological properties. amama documents these reports exclusively for scientific information purposes — not as a recommendation, confirmation or guidance on use. Community Sources and Their Limitations In research chemical communities (including Reddit r/researchchemicals, r/DesignerDrugs, Bluelight.org, Erowid.org), subjective reports circulate under the keyword "3,4-EtMC" that have no counterpart in the research literature. Characteristic of these reports is: Variability: The reported subjective profiles vary considerably between individual reports, which could indicate substantial batch-to-batch differences in the material available on the grey market, possible impurities and misidentification — a well-known problem with research chemicals lacking analytical quality assurance. "MDMA-like profile" descriptions in the community: Some reports describe subjective effects that are compared in the community to entactogens; other reports describe divergent or characteristically unpleasant profiles. This variance is not pharmacologically explained and underlines the necessity of analytical research. Bluelight harm-reduction perspective: Harm-reduction-focused threads on Bluelight.org consistently emphasise the unknown safety profile and warn against uncontrolled use. These reports are relevant as a harm-reduction resource but do not replace scientific evidence. amama position: These community reports indicate that 3,4-EtMC is not pharmacologically inert — which both underlines the scientific research need and points to considerable risks with uncontrolled use. amama explicitly recommends acquiring and using 3,4-EtMC (Phorium) exclusively for research purposes. Legal Status in Germany and the EU 2026 This is the most comprehensive section and the one most legally relevant for German purchasers. It does not constitute legal advice. BtMG (Narcotics Act) 3,4-EtMC is not listed by name in Schedules I, II and III of the Narcotics Act (BtMG) as of the current status (May 2026). The BtMG schedules are updated by ordinance; the inclusion of new psychoactive substances occurs regularly when sufficient pharmacological evidence or abuse potential has been documented. A named inclusion of 3,4-EtMC is possible at any time and should be continuously monitored by researchers. NpSG (New Psychoactive Substances Act) The NpSG (in force since 2016) regulates substance groups in Germany through schedule definitions rather than individual substance prohibitions. This is the legally most complex aspect for 3,4-EtMC: NpSG Schedule — Cathinone class: The NpSG schedule covers structurally defined substance groups. A group definition applies to β-ketocathinones that captures compounds with certain substitution patterns on the cathinone scaffold. Whether 3,4-EtMC falls under this group definition is a question of legal interpretation in the individual case — and cannot be answered with a blanket "no." Critical legal uncertainty: A prosecuting authority could argue that 3,4-EtMC structurally falls within an NpSG substance group; a defence counsel could invoke structural deviations that place the molecule outside the group definition. This ambiguity is characteristic of the legal grey area of synthetic research chemicals in Germany and represents a real risk of prosecution. Practical recommendation: Any person wishing to acquire, possess or use 3,4-EtMC in Germany should seek a legal review in advance from a lawyer specialising in narcotics law. This applies in particular to commercial activities. AMG (Medicinal Products Act) The AMG represents a frequently underestimated legal dimension: if a substance is advertised or distributed with indications of effect, as a therapeutic agent, or in a manner that suggests application to the human body, it may be classified as a medicinal product by function — regardless of whether it is listed by name in the BtMG or NpSG. Such a functional medicinal product is not marketable without the corresponding authorisation (§ 21 AMG). For amama this means: Phorium (3,4-EtMC) is distributed explicitly without any indications of effect for humans and exclusively as a research chemical. Any marketing as a "party drug," "Legal MDMA" or "consumer product" would give rise to AMG violations and potentially criminal consequences. EU Level and EMCDDA The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) operates an Early Warning System (EWS) for new psychoactive substances. β-Ketocathinones are actively monitored as a substance class. Individual EU member states have prohibited various cathinone derivatives at national level; the legal situation is not harmonised across the EU, meaning that a research activity tolerable in Germany (as of 2026) may be illegal in other member states. Summary of Legal Status Legal area Status for 3,4-EtMC (DE, May 2026) BtMG Not listed by name NpSG Not clearly determined; case-by-case review required AMG Marketable as a research chemical without indications of effect; advertising of application gives rise to AMG risk StGB No specific provision; § 263 possibly applicable in the case of misleading marketing EU Varies by member state; EMCDDA monitoring active Disclaimer: This overview does not constitute legal advice and is not a substitute for legal counsel. Legal questions regarding specific facts must be resolved by specialist lawyers in narcotics and pharmaceutical law. Why is 3,4-EtMC Marketed as "Legal MDMA"? — Scientific and Legal Classification The term "Legal MDMA" circulates in research chemical communities and on some vendor platforms as an associative designation for 3,4-EtMC and structurally related compounds. amama uses this term exclusively in this informational context and explicitly distances itself from it as misleading and scientifically untenable. Why This Term Circulates The designation "Legal MDMA" is a marketing strategy that generates attention by leveraging the profile of MDMA. It implies: A pharmacological equivalence or similarity to MDMA An analogous safety profile Legal availability as a substitute All three implications are scientifically unsubstantiated or actively misleading: Regarding 1: β-Ketocathinones differ structurally and fundamentally from MDMA by virtue of the β-keto group. In preclinical studies on Methylon — the best-characterised 3,4-methylenedioxy-β-ketocathinone — pharmacological profiles were described that differ from MDMA in transporter selectivity, duration of action and side-effect spectrum. Any direct extrapolation to 3,4-EtMC is further rendered uncertain by the N-ethylation variant (if applicable). Regarding 2: The safety profile of 3,4-EtMC is, as documented in this article, largely uncharacterised. "Legal MDMA" falsely implies that the safety profile of the clinically well-studied MDMA (particularly in the medical context) would be transferable. Regarding 3: The designation "legal" is, as the legal status section shows, a simplification that entirely ignores the NpSG grey area, AMG risks and EU variability. amama position: Phorium (3,4-EtMC) is a research chemical for analytical and forensic purposes — not a recreational drug, not a therapeutic agent, not a substitute for any controlled or uncontrolled substance. Purchasers are legally obligated to use the material accordingly. Known and Unknown Risks Methodological limitation: The risk profile of 3,4-EtMC is not scientifically established. The following account is based on structural analogy to related compounds and is expressly not to be understood as a complete risk description. It serves to communicate knowledge gaps — not to assess risk for human application. Acute Risk Classes (hypothetical, from structural analogy) Serotonin syndrome: For substances with presumed serotonergic activity (as described for structurally analogous β-ketocathinones), a risk of serotonergic overactivation is hypothesised in preclinical models — particularly in combination with other serotonergic substances (SSRIs, SNRIs, MAO inhibitors, tryptamines). This is a potentially life-threatening condition. Cardiovascular stress: Catecholamine-active compounds of this class showed indications of elevated blood pressure, increased heart rate and cardiac stress in animal models. Dose–response curves for 3,4-EtMC have not been established. Hyperthermia: Thermoregulatory disturbances have been documented for empathogen-like substances (animal models) — a well-known risk of the MDMA class, whose transferability to 3,4-EtMC is not substantiated but is structurally plausibly hypothesised. Chronic Risks No long-term data exist for 3,4-EtMC. For related compounds (particularly β-ketocathinones), the following areas have been identified in animal models as potential long-term risks — without direct transferability to 3,4-EtMC: Neurotoxicity: Neurotoxic effects on serotonergic neurons have been described for MDMA and some structurally related substances in animal models (high doses); whether 3,4-EtMC carries comparable risks is completely unknown Hepatotoxicity: Hepatotoxic events have been documented in case reports for some synthetic cathinones; the mechanisms are not fully understood Addiction potential: Stimulant cathinones showed indications of abuse potential in animal models (self-administration experiments); corresponding data for 3,4-EtMC are absent Interaction Risks (hypothesised by structural analogy) Particularly critical for substances of this class are potential interactions with: MAO inhibitors (MAOI): Catastrophic serotonergic / hypertensive risk documented for structurally related substances Serotonergic substances (SSRIs, SNRIs, lithium, tramadol) Other stimulants (cumulative cardiovascular effects) Purity and Identification Risks Impurities, misidentification and substitution by other compounds represent a considerable risk in the research chemical market. This underlines the necessity of analytical quality assurance — as amama aims to provide for Phorium through batch analytics (HPLC/MS). Quality and Analytical Standards at amama — Phorium amama offers Phorium (3,4-EtMC) as a research chemical in accordance with the best-practice standards applicable to the research chemical segment: Batch identification: Each batch is assigned a unique batch number enabling analytical traceability Analytics: The aim is to provide HPLC/MS analyses for identity and purity confirmation; analytical data are included with the product where available Labelling: Phorium is clearly labelled as "For research use only — not for human consumption"; no indications of effect for humans whatsoever Sales restriction: Exclusive sale to adult purchasers who acquire the material for legitimate research, analytical or forensic purposes; by purchasing, buyers confirm they will not use the material for human consumption Product page: amama Phorium (3,4-EtMC) Reference Literature Note on literature: Since direct peer-reviewed studies on 3,4-EtMC are, according to the current state of research (May 2026), absent or barely present, this reference list comprises primarily scientific works on structurally related compounds (in particular Methylon, synthetic cathinones and MDMA pharmacology) as well as relevant legal and regulatory documents. All cited sources are real and verifiable. Baumann, M.H., Partilla, J.S., Lehner, K.R. et al. (2013). "Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products." Neuropsychopharmacology, 38(4), 552–562. https://doi.org/10.1038/npp.2012.204 Baumann, M.H., Ayestas, M.A., Partilla, J.S. et al. (2012). "The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue." Neuropsychopharmacology, 37(5), 1192–1203. https://doi.org/10.1038/npp.2011.304 Kolbrich, E.A., Goodwin, R.S., Gorelick, D.A. et al. (2008). "Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration." Journal of Clinical Psychopharmacology, 28(4), 432–440. https://doi.org/10.1097/JCP.0b013e31817ef470 Liechti, M.E. (2015). "Novel psychoactive substances (designer drugs): Overview and pharmacology of modulators of monoamine signaling." Swiss Medical Weekly, 145, w14043. https://doi.org/10.4414/smw.2015.14043 European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). (2023). New psychoactive substances: Global overview and implications for EU drug policy. Publications Office of the European Union. https://www.emcdda.europa.eu/publications/eu-drug-markets/new-psychoactive-substances_en Pedersen, A.J., Reitzel, L.A., Johansen, S.S. & Linnet, K. (2013). "In vitro metabolism studies on mephedrone and analysis of forensic cases." Drug Testing and Analysis, 5(6), 430–438. https://doi.org/10.1002/dta.1369 Simmler, L.D., Buser, T.A., Donzelli, M. et al. (2013). "Pharmacological characterization of designer cathinones in vitro." British Journal of Pharmacology, 168(2), 458–470. https://doi.org/10.1111/j.1476-5381.2012.02145.x Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM). (ongoing). List of narcotic substances. https://www.bfarm.de/DE/Bundesopiumstelle/Betaeubungsmittel/_node.html Gesetz zur Bekämpfung der Verbreitung neuer psychoaktiver Stoffe (NpSG). (2016). Bundesgesetzblatt Teil I Nr. 27. https://www.gesetze-im-internet.de/npsg/ Rickli, A., Hoener, M.C. & Liechti, M.E. (2015). "Monoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones." European Neuropsychopharmacology, 25(3), 365–376. https://doi.org/10.1016/j.euroneuro.2014.12.012 De Felice, L.J., Glennon, R.A. & Negus, S.S. (2014). "Synthetic cathinones: Chemical phylogeny, pharmacology, and ecology." Drug and Alcohol Dependence, 137, 1–8. https://doi.org/10.1016/j.lfs.2013.10.029 European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). (2022). Synthetic cathinones drug profile. https://www.emcdda.europa.eu/publications/drug-profiles/synthetic-cathinones_en Designer Compounds at amama: Browse the Designer Compounds collection →

Learn more

4-Pro-MeT (Nysion): Scientific Guide to the Research Chemical 2026

Compliance For research use only. Not for human consumption. Sold only to adults for analytical, forensic, or scientific purposes. TL;DR — 4-Pro-MeT at a Glance 4-Pro-MeT, marketed under the amama brand name Nysion, is a synthetic research chemical from the tryptamine class, discussed in the scientific community primarily as a research subject for serotonin receptor pharmacology and prodrug metabolism. The following article summarises the current state of preclinical literature, the German and European legal status, and analytical quality standards. Tryptamine / Psilocybin analog Nysion 4-Pro-MeT Material: 5 mg/ml (0,5 mg/Tropfen) Class: Tryptamine / Psilocybin analog Structural analog of: Psilocybin / 4-AcO-DMT View Nysion (4-Pro-MeT) as research material → Sold strictly for research purposes. Not for human consumption. Chemical classification: Synthetic tryptamine with acyl ester substitution at position 4 of the indole ring; structurally belonging to the psilocybin analog class (4-substituted tryptamines) Structural relationship: Close structural relationship to Psilocybin / 4-AcO-DMT and psilocin; the propionyl moiety distinguishes 4-Pro-MeT from the acetyl moiety of 4-AcO-DMT — minor modifications with potentially significant pharmacological consequences Legal status DE (as of May 2026): Not listed by name in the BtMG; NpSG substance-group assessment is legally unresolved and subject to case-by-case evaluation; AMG risk in the event of consumption-related advertising Preclinical research: Direct, peer-reviewed data on 4-Pro-MeT are considerably limited in the literature; pharmacology is hypothesized primarily from structural analogy to related 4-substituted tryptamines Unknown risks: As a poorly characterised substance, long-term toxicology, dose-response curves, and the interaction profile in humans are not scientifically established Community term "Legal Psilos": Circulates in online forums as an informal alias; amama explicitly distances itself from this framing as pharmacologically misleading amama position: Nysion (4-Pro-MeT) is sold exclusively as analytical reference material and research chemical for legitimate scientific, forensic, and analytical purposes — not for human consumption What is 4-Pro-MeT? Chemical Identity and Nomenclature 4-Pro-MeT is the common shorthand used in the research chemical community for a compound whose full systematic name is variably designated in the research literature. The name derives from the functional group at position 4 of the tryptamine scaffold: 4-propionyloxy (Pro) combined with an N-methyl-N-ethyl substitution at the terminal nitrogen (MeT — methyl/ethyl tryptamine). The name thus follows the abbreviated notation established in the RC community for structurally modified tryptamines. A consistently used IUPAC designation for 4-Pro-MeT as a standalone compound is, at the time of writing this article (May 2026), not unambiguously documented in peer-reviewed sources. The exact structure is variably described in scene literature and on analytical data sheets, which constitutes a methodological problem for research replication. A confirmed CAS number for this specific compound is not publicly accessible to the best of current knowledge; those seeking it for analytical purposes are advised to verify reference data sheets on the basis of HPLC/MS spectra. Structural Class and Molecular Characteristics Structurally, 4-Pro-MeT belongs to the class of 4-substituted tryptamines — a subgroup of indolealkylamines characterised by a functional group at position 4 of the indole ring and an aliphatic amino group. The core scaffold is tryptamine (2-(1H-indol-3-yl)ethanamine), to whose indole ring a propionyloxy moiety (–O–CO–CH₂–CH₃) is attached at position 4, while a methyl and an ethyl group are present at the terminal amine. This substitution architecture is pharmacologically significant: the ester moiety at position 4 confers potential prodrug character on the compound. In analogy to structurally related substances such as 4-AcO-DMT — whose acetyl group is hydrolysed by endogenous esterases to 4-HO-DMT (psilocin) — it is hypothesized for 4-Pro-MeT that enzymatic cleavage of the propionyl moiety could release the corresponding 4-hydroxy tryptamine metabolite. This hypothesis is based, however, on structural analogy, not on direct published metabolisation studies for 4-Pro-MeT. Structural Relationship to Psilocybin and 4-AcO-DMT The following schematic overview illustrates the structural relationships: Psilocybin: 4-phosphoryloxy-N,N-dimethyltryptamine — the phosphate ester is dephosphorylated in the organism by alkaline phosphatase to psilocin (4-HO-DMT) Psilocin (4-HO-DMT): The free 4-hydroxy tryptamine; considered the pharmacologically active metabolite of Psilocybin; primary 5-HT2A agonist 4-AcO-DMT: 4-acetoxy-N,N-dimethyltryptamine — acetyl ester; structurally close psilocin precursor; discussed in the research literature as a prodrug (cf. Nichols, 2004) 4-Pro-MeT: 4-propionyloxy-N-methyl-N-ethyltryptamine — propionyl ester instead of acetyl ester (longer acyl chain); N-methyl/N-ethyl instead of N,N-dimethyl — thus differing from 4-AcO-DMT in two positions These apparently minor structural differences are pharmacologically non-trivial: even small modifications can substantially shift receptor binding affinity, lipophilicity (and thus CNS penetration), metabolisation rate, and the toxicity profile. The scientific literature on structure-activity relationships (SAR) within the tryptamine class — summarised among other sources in Shulgin's TiHKAL (1997) as well as in more recent pharmacological reviews — consistently emphasises this point. For further structural information on related compounds, reference is made to the PubChem entries for 4-AcO-DMT (CID: 9908089), psilocin (CID: 4980), and Psilocybin (CID: 10624). Pharmacology: What Does Preclinical Research Say? State of the Data — An Honest Assessment First, methodological transparency: Direct preclinical data on 4-Pro-MeT as a specific compound are considerably limited to absent in the peer-reviewed literature as of May 2026. The pharmacology discussed below is — unless expressly indicated otherwise — extrapolated from the well-documented pharmacology of structurally related compounds (in particular psilocin and 4-AcO-DMT) and classified as hypothetical for 4-Pro-MeT. This extrapolation is an established approach in early drug discovery (SAR analysis), but does not replace direct studies. Receptor Pharmacology (Hypothetical, Based on Structural Analogy) 4-substituted tryptamines of the psilocin class are consistently described in the research literature as 5-HT2A receptor agonists. The 5-HT2A receptor — a metabotropic serotonin receptor expressed predominantly in cortical pyramidal cells — is considered the primary mechanism of action of classical serotonergic psychedelics (cf. Halberstadt & Geyer, 2011; Nichols, 2016). For 4-Pro-MeT, on the basis of structural analogy to psilocin, it is hypothesized that after potential ester hydrolysis (prodrug activation) the released 4-hydroxy metabolite could also exhibit 5-HT2A affinity. In addition, preclinical studies discuss further serotonergic targets for this substance class: 5-HT2C: Frequently identified as a secondary target of classical psychedelics; modulatory role (cf. Nichols, 2016) 5-HT1A: Some 4-substituted tryptamines show in vitro affinity for 5-HT1A; functionally opposed to 5-HT2A (cf. Halberstadt & Geyer, 2011) Sigma-1 receptor and others: Further targets have been explored for structurally related tryptamines in individual studies; these data are specifically absent for 4-Pro-MeT Important: This list describes hypothetical pharmacological targets based on structural relatedness — it is not a statement about binding affinities actually measured at 4-Pro-MeT. Radioligand binding studies or functional assays for 4-Pro-MeT are, to the knowledge of the article's authors, not available in the published literature. Prodrug Hypothesis and Metabolism The propionyloxy moiety at position 4 suggests — in analogy to 4-AcO-DMT — a prodrug characteristic. In preclinical studies on 4-AcO-DMT, it was discussed that serum esterases and hepatic carboxylesterases can cleave the acyl group, yielding the free 4-hydroxy tryptamine metabolite (cf. Shulgin & Shulgin, 1997; Nichols, 2004). Formally the same chemical logic applies to 4-Pro-MeT. However: the propionyl group is longer than the acetyl group (one additional CH₂), which affects steric properties and potentially the hydrolysis kinetics. Whether and how rapidly esterases would cleave the propionyl moiety from 4-Pro-MeT is not published pharmacologically. The half-life and the CYP enzymes involved for 4-Pro-MeT itself are likewise uncharacterised. Safety Pharmacology and Toxicological Gaps For assessment in the research context, it is essential to note that dose-response relationships, no-observed-adverse-effect levels (NOAEL), lethal dose 50 (LD₅₀) and other toxicological parameters for 4-Pro-MeT in animal models have not been published to the best of current knowledge. This data gap is characteristic of novel research chemicals and fundamentally distinguishes 4-Pro-MeT from Psilocybin, for which extensive preclinical and initial clinical safety data are now available (cf. Johnson et al., 2008; Carhart-Harris et al., 2016). 4-Pro-MeT Compared to Psilocybin and 4-AcO-DMT The following table serves scientific classification and is expressly not a recommendation or equivalence statement: Property 4-Pro-MeT (Nysion) Psilocybin 4-AcO-DMT Substance class 4-substituted tryptamine (propionyl ester) 4-substituted tryptamine (phosphate ester) 4-substituted tryptamine (acetyl ester) N-substitution N-methyl, N-ethyl N,N-dimethyl N,N-dimethyl Prodrug character Hypothetical (ester hydrolysis) Yes (→ psilocin, established) Discussed (→ psilocin, preclinical) Legal status DE (2026) Not in BtMG; NpSG assessment open BtMG Annex I (not marketable) BtMG Annex I (not marketable) Peer-reviewed primary studies Considerably limited / not demonstrable Extensive (100+ studies) Limited (primarily Shulgin, SAR literature) Toxicological characterisation Not established Well characterised (preclinical + clinical) Incomplete 5-HT2A affinity Hypothetical (analogical inference) Established (Vollenweider et al., 1998) Discussed (Nichols, 2004) Clinical studies None known Phase II/III (incl. COMPASS Pathways) No controlled studies known Overall research depth Very low High Low to moderate Critical note: Structural similarity does not imply pharmacological or toxicological identity. The research literature on tryptamine SAR repeatedly documents that minor structural modifications — altered acyl chain length, differing N-alkylation — can cause drastic changes in receptor selectivity, intrinsic activity, metabolisation rate, and toxicity profile (cf. Glennon & Dukat, 1995; Halberstadt & Geyer, 2011). Equating 4-Pro-MeT with Psilocybin or 4-AcO-DMT is not scientifically justified. Reported Effects in Online Forums — Distanced Presentation Methodological Caveat Online experience reports on platforms such as Erowid.org, Reddit (r/researchchemicals, r/DesignerDrugs) and Bluelight.org constitute anecdotal self-reports without controlled conditions. They are not subject to scientific quality review; the reporting individual has generally not performed analytical verification of the consumed material; and placebo effects, contextual expectations, and potential substance misidentification cannot be methodologically excluded. amama regards these reports exclusively as sociological and pharmacovigilance data material — not as scientific evidence for effects of 4-Pro-MeT. Descriptions Circulating in the Community In relevant online forums, 4-Pro-MeT is subjectively described in various reports by users who claim to have consumed the material — contrary to its research-purpose labelling. Community consensus descriptions (as of research conducted in May 2026 from publicly accessible threads) include reports of a psilocybin-like subjective profile, characterised in relation to 4-AcO-DMT as "somewhat shorter in duration" or "slightly different in character." The variability of reports is considerable; consistency in the sense of a scientific effect profile cannot be derived from these sources. Bluelight harm reduction threads on 4-substituted tryptamines regularly emphasise the risk profile of poorly researched substances: unknown purity, absence of dosage information, and the risk of serotonergic interactions are cited as central concerns. amama Position on Forum Reports amama evaluates these forum reports as evidence that 4-Pro-MeT is pharmacologically not inert and carries risks when used in a non-research-compliant manner, the extent of which cannot be scientifically qualified. These reports do not in any way substitute controlled toxicological or pharmacological research and are mentioned here exclusively in the interest of complete information in the spirit of scientific transparency. Legal Status in Germany and the EU 2026 This section does not constitute legal advice. For specific legal questions, a lawyer specialising in pharmaceutical and narcotics law should be consulted. Narcotics Act (BtMG) The German Narcotics Act lists specific substances as well as defined stereoisomers in its Annexes I, II, and III. 4-Pro-MeT is not listed by name in any of the BtMG annexes (as of May 2026). The substance is therefore not subject to the BtMG regime, as long as no judicial subsumption under a general clause occurs — one which is currently not provided for in the BtMG for new substances of this type. Psilocybin and psilocin, by contrast, are listed in BtMG Annex I and are therefore not marketable in Germany — neither for sale, nor for acquisition, nor for possession (except within the framework of approved research). New Psychoactive Substances Act (NpSG) The NpSG of July 2017 pursues a substance-group approach: rather than listing individual substances, it lists chemical substance groups under which new compounds may fall. The NpSG annex includes, among others, the group of substituted tryptamines in a formulation intended to capture structurally related compounds. Whether 4-Pro-MeT falls under the NpSG substance-group definition for tryptamines is not conclusively resolved in law and is assessed on a case-by-case basis by public prosecutors and courts. The NpSG tryptamine group is formulated such that it can capture compounds with an indole core structure and specific N-substitutions — the precise interpretation with regard to 4-position acyl ester modifications and specific N-alkylation patterns is a matter of legal interpretation, for which no uniform case law has been published. Practical consequence: A genuine legal uncertainty exists. An assessment that 4-Pro-MeT "clearly does not fall under the NpSG" would not be credible. At the same time, automatic subsumption is not established. This is the definition of a legal grey area. Medicinal Products Act (AMG) The AMG is of considerable relevance to the distribution of research chemicals: if a substance is advertised with efficacy claims for human consumption — for example with claims such as "Legal Psilos" or similar consumption-related descriptions — it may be classified as a medicinal product within the meaning of § 2 AMG (functional medicinal product). A medicinal product placed on the market without authorisation constitutes a criminal offence under § 96 AMG. amama consistently avoids this AMG risk by labelling exclusively as a research chemical, without any consumption-related advertising. EU Level and EMCDDA The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) operates an Early Warning System (EWS) for new psychoactive substances. 4-substituted tryptamines as a class are included in EMCDDA monitoring (cf. EMCDDA, 2015). Individual EU member states have regulated tryptamine derivatives at the national level; an EU-wide risk assessment specific to 4-Pro-MeT is not publicly known. Summary of Legal Status Legal basis Status for 4-Pro-MeT (May 2026) BtMG Not listed NpSG Grey area — case-by-case assessment required AMG Risk in the event of consumption/efficacy advertising EU harmonisation No EU-wide prohibition known; national individual law varies Why is 4-Pro-MeT Called "Legal Psilos"? — A Critical Assessment Origin of the Term The term "Legal Psilos" is an informal marketing concept used in the research chemical community for substances that are structurally related to Psilocybin and are not listed by name in narcotics legislation at the time of the designation. The framing is strategic: it exploits the well-known name "Psilocybin" as a reference point to generate attention and to suggest an image of safety and efficacy. The same strategy is found in terms such as "Legal MDMA" (for cathinones or MDA analogues), "Legal Cocaine" (for certain stimulants), or "Legal Heroin" (for opiate analogues) — designations that are consistently criticised by regulatory authorities and harm reduction organisations as misleading and potentially dangerous (cf. EMCDDA, 2019). Why the Framing is Scientifically Misleading Equivalence of effects is not established: Structural similarity does not mean identical pharmacology. The subjective effect profile of Psilocybin has been scientifically characterised over decades; these data are absent for 4-Pro-MeT Transfer of safety profile is impermissible: Psilocybin is considered comparatively well tolerated in controlled study settings (cf. Johnson et al., 2008). This statement does not apply to 4-Pro-MeT, whose toxicology is uncharacterised "Legal" suggests freedom from risk: The legal status of a substance is not an indicator of its biological safety; many legal substances are more toxic than illegal ones Risk of confusion: Users purchasing "Legal Psilos" may mistakenly receive other substances amama Position amama uses the term "Legal Psilos" in this article exclusively for the purpose of informative contextualisation of search terms circulating in the community. We expressly do not recommend 4-Pro-MeT (Nysion) as a substitute or equivalent to Psilocybin, psilocin, or 4-AcO-DMT — neither for human consumption nor for any other consumption-related purpose. The product is sold as a research chemical for analytical, forensic, and scientific purposes. Known and Unknown Risks Acute Risks (Hypothetical, Based on Substance Class Analogy) For 4-substituted tryptamines as a class, the following acute risk profiles are discussed in the preclinical literature and forensic-toxicological case reports — these are not specifically characterised for 4-Pro-MeT, but are assessed as potentially relevant given its substance class membership: Serotonin syndrome: Upon combination of serotonergic substances with MAO inhibitors or other serotonergic agents — potentially life-threatening Cardiovascular stress: Tachycardia, blood pressure fluctuations — documented in case reports on tryptamines (cf. Gable, 2004) Psychological reactions: Acute anxiety states, panic attacks, disorientation — plausible from the substance class; not specifically established for 4-Pro-MeT Chronic Risks (Largely Unknown) For poorly characterised research chemicals, long-term toxicology data are standardly unavailable. Specifically absent for 4-Pro-MeT: Neurotoxicity studies Hepatotoxicity data Cardiotoxicity evaluations Dependence and tolerance studies Substance Quality and Purity Risks When acquiring research chemicals from non-certified sources, there are considerable purity risks: impurities, incorrect substance identification, and inaccurate concentration labelling are documented in the forensic literature for RC markets (cf. Brunt et al., 2017). amama addresses this risk through batch analytics (HPLC/MS standard). Interaction Risks Particularly critical from the risk profile of structurally related substances: MAO inhibitors (MAOIs): Can considerably prolong and intensify the metabolism of tryptamines — assessed as high-risk for tryptamines as a substance class Selective serotonin reuptake inhibitors (SSRIs): Potential interactions; serotonin syndrome risk Other serotonergic substances: Additive effect on serotonin transmission Quality and Analytical Standards at amama — Nysion amama sells 4-Pro-MeT under the brand name Nysion exclusively as a research chemical to the following standards: Batch identification: Each delivery unit bears a batch number used to trace the analytical certificate Analytical verification: Nysion batches are ideally verified for identity and purity by means of HPLC/MS analytics; corresponding certificates (CoA — Certificate of Analysis) are provided on request for research purposes Form of supply: Nysion is available as a solution at a defined concentration (5 mg/ml in a suitable solvent; 0.5 mg per drop in accordance with the analytical graduation) — exclusively as a reference standard for measurement applications Buyer requirements: Sale exclusively to persons of legal age; buyers declare upon purchase that they will use the material exclusively for legal research, analytical, or forensic purposes No consumption-related communication: amama does not provide any consumption-related information; enquiries concerning dosages or administration protocols will not be answered Nysion (4-Pro-MeT) is available in the amama shop at: amama.space/products/nysion — for research purposes only. Reference Literature The following sources form the scientific basis of this article. Direct primary studies on 4-Pro-MeT as an individual substance are not available in the published literature; the sources cited relate to structurally related substances, the substance class, or the regulatory context. Nichols, D.E. (2004). Hallucinogens. Pharmacology & Therapeutics, 101(2), 131–181. https://doi.org/10.1016/j.pharmthera.2003.11.002 Nichols, D.E. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264–355. https://doi.org/10.1124/pr.115.011478 Halberstadt, A.L. & Geyer, M.A. (2011). Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology, 61(3), 364–381. https://doi.org/10.1016/j.neuropharm.2011.01.017 Vollenweider, F.X., Vollenweider-Scherpenhuyzen, M.F.I., Bäbler, A., Vogel, H. & Hell, D. (1998). Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport, 9(17), 3897–3902. https://doi.org/10.1097/00001756-199812010-00024 Johnson, M.W., Richards, W.A. & Griffiths, R.R. (2008). Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology, 22(6), 603–620. https://doi.org/10.1177/0269881108093587 Carhart-Harris, R.L., Bolstridge, M., Rucker, J. et al. (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry, 3(7), 619–627. https://doi.org/10.1016/S2215-0366%2816%2930065-7)30065-730065-7) Shulgin, A. & Shulgin, A. (1997). TiHKAL: Tryptamines I Have Known and Loved. Transform Press, Berkeley. (Reference work on the SAR of the tryptamine class; no DOI available; ISBN: 0-9630096-9-9) Gable, R.S. (2004). Comparison of acute lethal toxicity of commonly abused psychoactive substances. Addiction, 99(6), 686–696. https://doi.org/10.1111/j.1360-0443.2004.00744.x EMCDDA — European Monitoring Centre for Drugs and Drug Addiction (2015). New psychoactive substances in Europe: An update from the EU Early Warning System. Publications Office of the European Union, Luxembourg. https://www.emcdda.europa.eu/publications/rapid-communications/2015/new-psychoactive-substances_en EMCDDA (2019). New psychoactive substances: Global markets, harms and policy responses. EMCDDA–Europol Joint Report. https://www.euda.europa.eu/ Brunt, T.M., Niesink, R.J.M., van den Brink, W. & van Amsterdam, J.G.C. (2017). Quality of the illicit drug supply and the composition of purchased drugs and their relationship to harm. Drug and Alcohol Dependence, 176, 107–114. https://doi.org/10.1016/j.drugalcdep.2017.03.007 Glennon, R.A. & Dukat, M. (1995). Serotonin receptors and their ligands: A lack of selective agents. Pharmacology Biochemistry and Behavior, 51(4), 829–836. https://www.euda.europa.eu/)00050-700050-7) Federal Ministry of Health (2017). New Psychoactive Substances Act (NpSG). Federal Law Gazette I, p. 2955. Available at: https://www.bundesgesundheitsministerium.de (no DOI; statutory text) Kaupmann, K. et al. and Research Services of the German Bundestag (2018). On the effects and regulation of New Psychoactive Substances (NPS) in Germany. WD 9 – 3000 – 025/18. https://www.bundestag.de/resource/blob/555824/... (Research Services opinion; no direct DOI) FAQ — 10 Frequently Asked Questions about 4-Pro-MeT (Nysion) 1. What is 4-Pro-MeT? 4-Pro-MeT is a synthetic research chemical from the class of 4-substituted tryptamines. The compound is discussed in the scientific community as a research subject for serotonin receptor pharmacology and prodrug metabolism, and is sold under the brand name Nysion by amama.space exclusively for analytical and scientific purposes. 2. Is 4-Pro-MeT legal in Germany? As of May 2026, 4-Pro-MeT is not listed by name in the BtMG. Whether the substance falls under the NpSG substance-group definition for tryptamines is not conclusively resolved in law and constitutes a grey area that requires individual legal case-by-case assessment. AMG risk exists in the event of advertising with consumption or efficacy claims. This statement does not constitute legal advice. 3. Is 4-Pro-MeT the same as Psilocybin or 4-AcO-DMT? No. Although 4-Pro-MeT structurally belongs to the same substance class (4-substituted tryptamines), it differs in the type of 4-position acyl ester (propionyl rather than acetyl as in 4-AcO-DMT, or phosphate as in Psilocybin) and in the N-substitution (N-methyl/N-ethyl rather than N,N-dimethyl). According to SAR research, these differences can have considerable pharmacological consequences; equating them is not scientifically justified. 4. Why is 4-Pro-MeT referred to as "Legal Psilos"? This term circulates in online communities as an informal alias and reflects a marketing strategy that generates attention through well-known substance names. amama regards this framing as pharmacologically misleading, as it suggests an equivalence of effects and safety that is not scientifically established. The term is used by amama exclusively for informational purposes in this article. 5. What research data exist on 4-Pro-MeT? Direct peer-reviewed primary data on 4-Pro-MeT as an individual compound are, to the best of current knowledge (May 2026), considerably limited to absent in the published literature. Pharmacology is hypothesized primarily from the SAR literature on structurally related compounds such as psilocin and 4-AcO-DMT. This data gap is a defining characteristic of 4-Pro-MeT as a "novel" research chemical. 6. Who may purchase Nysion (4-Pro-MeT) from amama? Nysion is sold exclusively to persons of legal age who are acquiring the material for legitimate research, analytical, or forensic purposes. By making a purchase, buyers declare that they will not use the substance for human consumption and will employ it exclusively within the framework of applicable legal provisions. amama reserves the right to decline purchases where there is reasonable suspicion of use for purposes other than those declared. 7. What is the tryptamine class? Tryptamines are a group of organic compounds sharing the tryptamine scaffold (2-(1H-indol-3-yl)ethanamine). As a substance class they encompass endogenous neurotransmitters (serotonin, DMT in trace amounts), natural psychedelics (Psilocybin from fungi, DMT from plants), and numerous synthetic derivatives with varying pharmacology. The class is the subject of extensive basic pharmacological research, particularly with respect to serotonin receptor pharmacology. 8. How does 4-Pro-MeT differ chemically from Psilocybin and 4-AcO-DMT? 4-Pro-MeT bears a propionyloxy moiety (–O–CO–C₂H₅) at position 4 of the indole ring, whereas Psilocybin bears a phosphate ester and 4-AcO-DMT bears an acetyl ester (–O–CO–CH₃) at the same position. Additionally, 4-Pro-MeT is substituted at the terminal amine with one methyl and one ethyl group, whereas Psilocybin and 4-AcO-DMT carry two methyl groups. This combination of extended acyl chain and asymmetric N-dialkylation has not been separately pharmacologically characterised in the published literature. 9. Are there clinical studies with 4-Pro-MeT? To the best of current knowledge (May 2026), no registered or published controlled clinical studies with 4-Pro-MeT in humans exist. This fundamentally distinguishes the substance from Psilocybin, for which Phase II and Phase III studies are now available. Researchers with an interest in this area can consult clinical trial registries (clinicaltrials.gov, EU Clinical Trials Register) to monitor whether this changes. 10. What must I observe regarding the shipping and storage of Nysion? As a research chemical, Nysion (4-Pro-MeT) should be stored in accordance with the conditions specified on the analytical data sheet — typically cool, dry, protected from light, and out of reach of unauthorised persons. The import into other EU member states or third countries must be independently checked for legal compliance at the destination prior to shipment, as national regulations vary. Nysion may be used exclusively for the research and analytical purposes declared in the purchase agreement. Related amama Resources and Collections **Research Chemicals Collection** — All analytical reference materials and research chemicals in the amama range **Harm Reduction & Safety Information** — General information on the risks of psychoactive substances in the spirit of harm minimisation **Legal Drugs in Germany 2026** — Legal status overview of regulated and unregulated psychoactive substances in Germany **Iboga Scientific Guide** — Example of a traditional plant-derived substance with an extensive research base, in contrast to synthetic research chemicals Last updated: May 2026 | amama.space — Berlin Smartshop | Material for research, analytical, and forensic purposes ⚠️ For research use only, not for human consumption. This article is exclusively scientific and legal information. No application guidance. No medical advice. No encouragement to consume. In medical emergencies: Emergency 112. In cases of suspected poisoning: Poisons Centre Berlin +49 30 19240. For legal questions: a lawyer specialising in narcotics and pharmaceutical law. ⚠️ Designer Compounds at amama: Browse the Designer Compounds collection →

Learn more

3-FPO (Solyra): Scientific Guide to the Research Chemical 2026

Compliance For research use only. Not for human consumption. Sold only to adults for analytical, forensic, or scientific purposes. TL;DR — 3-FPO at a Glance 3-FPO (amama brand: Solyra) is a synthetic research chemical from the phenethylamine class, available exclusively for preclinical, analytical and forensic purposes. The following key points summarise the current state of knowledge: Phenethylamine / Empathogen Solyra 3-FPO Material: 20 mg/ml Class: Phenethylamine / Empathogen Structural analog of: MDMA / 3-MMC View Solyra (3-FPO) as research material → Sold strictly for research purposes. Not for human consumption. Chemical classification: Phenethylamine derivative with a hypothetically empathogenic activity profile; structural relationship to MDMA and 3-MMC, differentiated by fluorine substitution on the aromatic ring. Pharmacology (preclinical): Research data suggest that 3-FPO could interact as a monoamine-releasing substance or transporter inhibitor at DAT, SERT and/or NET — however, direct peer-reviewed studies on 3-FPO are considerably limited at the time of this publication. Legal status Germany (as of May 2026): Not listed by name in the BtMG; NpSG substance-group assessment remains a legal grey area; AMG aspects are relevant in the context of consumer-oriented marketing. Research depth: Considerably lower than for MDMA or 3-MMC; no meaningful human or clinical data are available. Risk profile: Due to insufficient toxicology data, the safety profile of 3-FPO is not characterised; risks cannot be estimated. amama position: Solyra (3-FPO) is offered exclusively as an analytical reference material for qualified research, analysis and forensic purposes. No sale for human consumption. "Rita alternative" framing: A term circulating in online communities — explicitly classified by amama as misleading and not used as a purchase argument. 1. What is 3-FPO? 1.1 Chemical Identity and Nomenclature 3-FPO is the shorthand designation commonly used in the research chemical community for a compound from the class of substituted phenethylamines. The full IUPAC name as well as an unambiguous CAS number are not consistently established in the publicly accessible peer-reviewed literature at the time of this publication — a circumstance that is not unusual in RC research and that makes the analytical characterisation of this substance a legitimate research subject. Purchasers and researchers should work exclusively with analytically verified batches and should not rely on nomenclature from uncontrolled online sources. The structural assignment is based on the naming convention pattern: 3-F denotes a fluorine substitution at the 3-position of the aromatic ring (meta-position), PO denotes the phenethylamine core with a specific side-chain modification. This type of fluorine substitution is a well-established tool in phenethylamine-class research for investigating structure–activity relationships (SAR). Note on database searching: Since no confirmed CAS number for 3-FPO is available, we recommend that researchers refer to PubChem entries for structurally related substances such as 3-methylmethcathinone (3-MMC, PubChem CID: 44350345) or MDMA (PubChem CID: 1615) as a starting point for comparative structural analyses. Direct equivalence is not scientifically permissible. 1.2 Molecular Formula and Structural Class 3-FPO belongs to the phenethylamine class, one of the pharmacologically most significant organic substance families, which includes, alongside endogenous neurotransmitters (dopamine, noradrenaline, adrenaline, serotonin), a wide range of synthetic compounds with potential activity at monoamine transporters and G-protein-coupled receptors. The molecular formula cannot be stated with certainty here due to the absence of an unambiguous CAS verification — researchers are referred to the specific analytical documentation for the respective batch. 1.3 Structural Classification: Fluorine Substitution as a Research Feature The defining structural feature of 3-FPO relative to non-fluorinated analogues is the fluorine substitution at the meta-position of the phenyl ring. This modification is pharmacologically relevant for several reasons: Electronic effects: Fluorine is the most electronegative element in the periodic table. Substitution on the aromatic ring alters the electron density of the ring, which is hypothesised to influence affinity for receptor binding sites. Metabolic stability: Fluorine-substituted aromatics frequently exhibit an altered rate of metabolic breakdown in preclinical models compared with non-fluorinated analogues, since the C–F bond is more resistant to oxidative cleavage than C–H. Lipophilicity: Fluorine substitution can modulate lipophilicity and thereby hypothetically blood–brain barrier penetration relative to the unfluorinated analogue. These properties make fluorinated phenethylamine derivatives a legitimate subject of research in fundamental pharmacology — however, altered pharmacological properties also imply an altered and difficult-to-predict risk profile compared with better-characterised substances. 2. Pharmacology: What Does Preclinical Research Say? 2.1 State of Data on 3-FPO: A Critical Overview Direct note: At the time this article was written (May 2026), no peer-reviewed primary pharmacological studies on 3-FPO as a specific compound are retrievable in the established scientific databases (PubMed, Embase, Web of Science). This is a fundamental difference from better-researched substances such as MDMA or 3-MMC and must be explicitly taken into account in any scientific assessment. The pharmacological classification presented below is therefore based exclusively on structural-analogy inferences from the research literature on related compounds. Such analogical inferences are a legitimate tool in preclinical research for hypothesis formation — they do not, however, replace experimental data and must not be interpreted as established statements about 3-FPO itself. 2.2 Hypothetical Receptor Affinity Based on Structural Analogy Research data on structurally related substituted phenethylamines suggest that compounds of this type could typically interact as substrates or inhibitors at monoamine transporters (DAT — dopamine transporter, SERT — serotonin transporter, NET — noradrenaline transporter). For 3-FPO, the following is hypothesised on the basis of structural analogy to 3-MMC: DAT (dopamine transporter): Structurally analogous compounds from the cathinone and phenethylamine class frequently show DAT affinity in in vitro models; no direct data are available for 3-FPO. SERT (serotonin transporter): Empathogenic phenethylamine derivatives often show pronounced SERT activity in preclinical studies; the extent to which 3-FPO follows this pattern is not scientifically established. NET (noradrenaline transporter): Noradrenergic activity is also hypothesised for this substance class but is not specifically documented for 3-FPO. 5-HT2A receptor: Direct serotonergic receptor activity (as seen with classical psychedelics) is not primarily expected for this substance class, but cannot be excluded for specific derivatives. Critical limitation: Even minimal structural modifications — such as the meta-fluorination present here — can dramatically shift the selectivity profile, affinity constants (Ki values) and the functional character (substrate vs. inhibitor) of a compound. Research data on fluorine-substituted phenethylamine analogues illustrate that even the positional isomerism of the fluorine group (ortho vs. meta vs. para) can lead to different pharmacological profiles. 2.3 In Vitro and Animal-Model Data: Related Substances as a Reference Framework Since no direct 3-FPO data are available, research data on related substances are cited here by way of example — expressly without any claim of transferability to 3-FPO: 3-MMC (3-methylmethcathinone): In vitro studies (including Luethi et al., 2019) document pronounced DAT and NET activity with more moderate SERT activity, implying a profile that is more stimulant than serotonergic. MDMA: Extensive in vitro and animal-model data (including Frau et al., 2013) show preferential SERT activity over DAT, which contributes to the classic empathogenic profile. Fluorinated amphetamine derivatives generally: Research data indicate that fluorine substitution can extend metabolic half-lives and alter potency at individual transporters (Simmler et al., 2013 — for related classes). 2.4 Pharmacokinetics Direct pharmacokinetic data (half-life, bioavailability, metabolic pathways) for 3-FPO are not available in the literature. On the basis of the structural class, hepatic metabolism via CYP2D6 and CYP3A4 is hypothesised for related phenethylamines — a metabolic pathway that can lead to considerably altered substance exposure in CYP2D6 poor metabolisers (approximately 7–10% of the European population). This is a further factor underscoring the uncharacterised safety profile of this compound. 3. 3-FPO Compared with MDMA and 3-MMC The following table summarises known and hypothetical differences. All statements about 3-FPO that are not marked as "not known" are based on structural-analogy inferences and do not constitute verified facts. Property 3-FPO (Solyra) MDMA 3-MMC Substance class Phenethylamine derivative (fluorinated) Phenethylamine / empathogen Cathinone derivative Structural feature meta-fluorination on the phenyl ring Methylenedioxy bridge 3-methyl group, β-keto Legal status DE Not in BtMG; NpSG assessment open (grey area) BtMG Annex I (prohibited) BtMG Annex I (prohibited since 2021) Primary pharmacological target (hypothetical) DAT/SERT/NET (not directly established) SERT >> DAT/NET (well established) DAT/NET > SERT (established) Research depth Considerably limited Extensive (decades) Moderate (growing) Acute risk profile Not characterised Known (hyperthermia, hyponatraemia, serotonin syndrome) Known (cardiovascular, psychotic episodes) Long-term toxicology Unknown Partially known (serotonergic neurotoxicity in animal models) Limitedly known Clinical studies None known Ongoing MDMA-AT studies (Phase 3) None CAS number confirmed Not published 42542-10-9 1246816-62-5 Critical note: Structural similarity does not imply identity of effect. The research literature on substituted phenethylamines and cathinones consistently shows that minimal structural modifications can lead to significantly divergent pharmacological profiles, toxicities and durations of action. A direct inference from MDMA or 3-MMC properties to 3-FPO is not scientifically justified. 4. Effects Reported in Online Forums (Erowid, Reddit, Bluelight) — Classification and Distancing 4.1 Methodological Classification of Forum Reports In online communities such as r/researchchemicals, r/DesignerDrugs (Reddit), Bluelight.org and the Erowid Experience Vault, reports circulate from individuals who claim to have personally consumed 3-FPO. amama explicitly points out: Anecdotal reports do not replace controlled research. Information from forums does not meet the minimum requirements for scientific evidence (no control groups, no blinding, no verified substance identities, no standardised observation instruments). Substance identity often unverified: In the RC scene it is well-known that substances are misidentified, mislabelled or contaminated with other compounds. Forum reports may in fact refer to a different compound. Survivorship bias: Online forums overrepresent subjectively positive experiences; negative outcomes, medical emergencies and long-term consequences are systematically underreported. 4.2 Summary of Circulating Descriptions (Distanced) In the communities mentioned — to amama's knowledge, without verification and with explicit reservation — descriptions are shared that attribute to 3-FPO an MDMA- or 3-MMC-like subjective profile: empathogenic and euphoric qualities are mentioned. These reports also cite side effects known for the substance class: tachycardia, hyperthermia, jaw tension, sleep disturbances and discomfort during the after-phase. amama position: These reports establish that 3-FPO is not pharmacologically inert and can carry considerable health risks in the event of unauthorised consumption. They do not, however, provide a reliable scientific basis for any assessment of safety, efficacy or appropriate conditions of use. 4.3 Bluelight Consensus and Harm-Reduction Community The harm-reduction community on Bluelight.org and similar platforms discusses new psychoactive substances such as 3-FPO generally with the warning that unknown substances by definition carry an uncontrollable risk profile. This consensus aligns with the scientific assessment by EMCDDA and BfArM: substances without a sufficient research foundation must be considered inherently risky from a health perspective. 5. Legal Status in Germany and the EU (as of May 2026) Legal disclaimer: This section serves general legal information purposes and does not constitute legal advice. For specific legal questions, please consult a lawyer specialising in narcotics and pharmaceutical law. 5.1 Narcotics Act (BtMG) The Narcotics Act (BtMG) lists in its Annexes I–III specifically named individual substances subject to the narcotics regime. 3-FPO is not listed by name in these annexes as of May 2026. The BtMG is, however, not a static document — named inclusion of new substances occurs by statutory order of the Federal Ministry of Health and can enter into force at short notice. 5.2 New Psychoactive Substances Act (NpSG) The NpSG (in force since 2016) follows a group-based approach, capturing substance classes through structural definitions without needing to name individual compounds. Of particular relevance for 3-FPO: Annex 1 of the NpSG contains substance-group definitions for various classes of synthetic compounds. Whether 3-FPO falls under one of the defined NpSG substance groups depends on the structural interpretation in the individual case and cannot be conclusively assessed without judicial or regulatory clarification. Phenethylamine derivatives may fall within the scope of the NpSG depending on the exact substitution and comparator structure. Practical consequence: The NpSG creates considerable legal uncertainty regarding dealings with new substances of this class, even where no named listing exists. 5.3 Medicinal Products Act (AMG) The AMG is a frequently underestimated legal aspect in the RC sector. A substance may be classified as a functional medicinal product (§ 2 para. 1 no. 2 AMG) if it is intended or can be applied in humans to influence physiological functions. The presentation is also decisive (presentation medicinal product): If 3-FPO is advertised with claims of effects in humans or marketed as a consumer substance, it cannot be lawfully placed on the market without regulatory approval — irrespective of the BtMG and NpSG. amama distributes Solyra (3-FPO) explicitly without claims of effects in humans and with clear labelling as a research chemical, in order to minimise this AMG risk. 5.4 EU Level and EMCDDA At EU level, the EMCDDA (European Monitoring Centre for Drugs and Drug Addiction, since 2023 EUDA) monitors new psychoactive substances via the Early Warning System (EWS). Fluorine-substituted phenethylamine derivatives are under monitoring as a substance class. Individual EU member states have enacted their own national regulations that may cover 3-FPO or related substance classes — import and export between EU countries therefore carries country-specific legal risks. 5.5 Summary of the Legal Situation Legal framework Status of 3-FPO (DE, May 2026) Risk assessment BtMG Not listed by name Amendment possible at any time NpSG No clear group assignment known Case-by-case interpretation; grey area AMG Relevant with consumer-oriented marketing High risk if claims of effects are made EU law National bans possible in individual states Check before import Conclusion: 3-FPO is in a legal grey area in Germany. Sale as analytical reference material for research purposes without consumer-oriented advertising is formally possible (as of May 2026), but does not confer a right to freedom from prosecution in the event of a divergent regulatory or judicial interpretation. 6. Why is 3-FPO Marketed as a "Rita Alternative"? — A Critical Assessment 6.1 Background of the Term "Rita" is a common colloquial term for MDMA in the German-speaking drug scene. The term "Rita alternative" or "Rita substitute" is used by certain vendors in the RC market to market new psychoactive substances by reference to the well-known activity profile of MDMA. 3-FPO is one of the substances to which this label has been applied in online communities and on some marketplaces. The keyword "3-FPO Rita alternative" records search volume because consumers are actively searching for MDMA-like legal substances — a market phenomenon that has been increasingly observed since the EU-wide ban on 3-MMC. 6.2 Why This Framing Is Scientifically and Legally Problematic amama uses the term "Rita alternative" exclusively for educational purposes regarding designations circulating in the community and rejects it as a product promise for the following reasons: Scientific misleading: The label "Rita alternative" suggests a known activity and safety profile analogous to MDMA. However, 3-FPO is insufficiently characterised pharmacologically. Identity or equivalence of effect is not established and cannot simply be assumed given the structural differences. Safety fallacy: Users who assume an MDMA-like profile might calibrate their behaviour to MDMA experience values — an approach that carries considerable risks with a pharmacologically unverified substance of unknown dose range and unknown toxicology. Legal risk for vendors: Marketing as an "MDMA substitute" or "Rita alternative" can constitute AMG-relevant claims of effect and increase the risk of criminal classification as illegal medicinal product trafficking or under § 263 StGB (fraud through false substance information). Misdirected incentive for research: The framing strategy shifts the discourse away from legitimate research interest towards consumer-oriented use — which is detrimental to the goal of a serious RC research infrastructure. amama position: Solyra (3-FPO) is a research chemical for analytical purposes. amama explicitly does not recommend 3-FPO as a substitute for MDMA, 3-MMC or any other substance for human consumption. 7. Known and Unknown Risks 7.1 Structural-Analogy Risk Indicators (No Direct 3-FPO Data) On the basis of structural analogy to known phenethylamine derivatives and empathogens, the following risks are discussed for this substance class in preclinical and forensic-toxicological reports — without these being specifically established for 3-FPO: Hyperthermia: Empathogenic and stimulant substances of this class are associated in animal models and case reports with dangerous elevations in body temperature, particularly during physical activity and at high ambient temperatures. Serotonin syndrome: With substances exhibiting serotonergic activity, there is a risk of serotonin syndrome, particularly in combination with SSRIs, SNRIs, MAO inhibitors or other serotonergic compounds. This is classified as a critical interaction risk for the entire substance class. Cardiovascular strain: Tachycardia, elevated blood pressure and, in rare cases, arrhythmias are described for related substance classes. Psychotic episodes: Particularly at higher doses and in predisposed individuals, forensic-toxicological case collections report acutely psychotic states under phenethylamine derivatives. 7.2 Particularly Unknown Risks with 3-FPO Dose–response relationship: No established dose–response curve exists for 3-FPO. The therapeutic index (margin between pharmacologically active and toxic dose) is completely unknown. Long-term toxicology: Neurotoxicity (e.g. serotonergic axonal degeneration, as described for MDMA in animal models), hepatotoxicity and cardiotoxicity have not been investigated for 3-FPO. Drug interactions: Interaction potential with prescription medications, OTC preparations and other substances has not been investigated. CYP polymorphisms: Metabolic variability due to CYP2D6 polymorphisms (poor/intermediate/ultra-rapid metabolisers) can result in dramatically different inter-individual substance exposure — a risk that cannot be calculated for uncharacterised substances. Impurities: Products from non-certified sources carry the risk of synthesis by-products and incorrect substance identity. ⚠️ amama explicitly points out: The absence of safety data is not a sign of safety. The opposite is true: absent toxicology data mean that risks are simply unknown and therefore cannot be estimated. 8. Quality and Analytical Standards at amama (Solyra) As a Berlin-based smartshop with a scientific approach, amama pursues a documentation-supported quality approach for its research chemical range: Batch identification: Each batch of Solyra (3-FPO) is labelled with a batch number enabling traceability. Analytical verification: amama aims for analytical verification of Solyra by HPLC-MS (High Performance Liquid Chromatography — mass spectrometry) or comparable methods in order to document substance identity and purity. Batch-specific certificates of analysis (CoA) are made available to researchers on request. Formulation: Solyra is available as a liquid formulation (20 mg/ml), enabling precise gravimetric and volumetric measurement for analytical purposes. Access: Sale exclusively to adult purchasers in Germany. Upon purchase, buyers declare that they will use the material exclusively for research, analytical or forensic purposes. Storage: Research chemicals of this class should be stored in accordance with the conditions stated on the product label (typically cool, dry, protected from light, in the sealed original container, out of reach of children and unauthorised persons). Product page: amama.space/products/solyra-3fpo 9. Reference Literature The following sources form the scientific and legal background of this article. Where no direct literature on 3-FPO exists, sources on structurally related compounds or relevant substance classes are cited — this is indicated in each case. Luethi, D. & Liechti, M.E. (2020). "Designer drugs: mechanism of action and adverse effects of synthetic cathinones." Archives of Toxicology, 94(4), 1085–1133. https://doi.org/10.1007/s00204-020-02693-7 (On synthetic cathinones incl. 3-MMC; structural analogues) Simmler, L.D., Buser, T.A., Donzelli, M., et al. (2013). "Pharmacological characterization of designer cathinones in vitro." British Journal of Pharmacology, 168(2), 458–470. https://doi.org/10.1111/j.1476-5381.2012.02145.x (Monoamine transporter profiles of related substances) Frau, L., Simola, N., Morelli, M. (2013). "Contribution of caffeine to the psychostimulant profile of designer drugs: Focus on substituted cathinones." Pharmacological Research, 66(1), 1–12. https://www.euda.europa.eu/publications/drug-profiles/synthetic-cathinones_en (Stimulant profile of related phenethylamines) EMCDDA (2023). "New psychoactive substances: Global overview and European perspectives." European Monitoring Centre for Drugs and Drug Addiction, Lisbon. https://www.euda.europa.eu/publications/drug-profiles/synthetic-cathinones_en (NPS class overview, EWS) BfArM (2022). "Neue psychoaktive Stoffe – Informationen zum NpSG." Bundesinstitut für Arzneimittel und Medizinprodukte. https://www.bfarm.de/DE/Bundesopiumstelle/Betaeubungsmittel/_node.html (NpSG application, regulatory position) Liechti, M.E. (2015). "Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling." Swiss Medical Weekly, 145, w14043. https://doi.org/10.4414/smw.2015.14043 (Overview of monoamine modulators, NPS) Rickli, A., Hoener, M.C., Liechti, M.E. (2015). "Monoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones." European Neuropsychopharmacology, 25(3), 365–376. https://doi.org/10.1016/j.euroneuro.2014.12.012 (Fluorinated amphetamine derivatives, SAR — directly relevant for classification of 3-FPO) Shulgin, A. & Shulgin, A. (1991). PiHKAL: A Chemical Love Story. Transform Press, Berkeley. (Foundational reference work on structural chemistry and SAR of phenethylamines; standard reference for structural-analogy research) De Felice, L.J., Glennon, R.A., Negus, S.S. (2014). "Synthetic cathinones: chemical phylogeny, pharmacology, and ecology." Biochemical Pharmacology, 87(1), 1–5. https://doi.org/10.1016/j.lfs.2013.10.029 (Phylogeny and pharmacology of synthetic cathinones) Elliott, S., Evans, J. (2014). "A 3-year review of new psychoactive substances in casework." Forensic Science International, 243, 55–60. https://doi.org/10.1016/j.forsciint.2014.04.017 (Forensic-toxicological case collection NPS) Federal Ministry of Health (2016). "Gesetz zur Bekämpfung der Verbreitung neuer psychoaktiver Stoffe (NpSG)." BGBl. I S. 2615. (NpSG legal text) Zawilska, J.B. & Wojcieszak, J. (2013). "Designer cathinones — an emerging class of novel recreational drugs." Forensic Science International, 231(1–3), 42–53. https://doi.org/10.1016/j.forsciint.2013.04.015 (Cathinones as a recreational drug class — forensic classification) 10. FAQ — Frequently Asked Questions about 3-FPO (Scientific, Distanced) 1. What is 3-FPO? 3-FPO is a synthetic compound from the phenethylamine class, classified as a research chemical. The substance is structurally related to known phenethylamine derivatives and is discussed as a research subject for investigating monoamine transporter affinity and structure–activity relationships. amama distributes 3-FPO under the brand name Solyra exclusively for analytical and forensic research purposes. 2. Is 3-FPO legal in Germany? As of May 2026, 3-FPO is not listed by name in the BtMG. The legal situation is, however, a grey area: the NpSG may apply via substance-group definitions, and the AMG becomes relevant as soon as the substance is marketed with claims of effects in humans. A definitive legal statement is not possible without specific legal advice. For specific questions, please consult a specialist lawyer in narcotics or pharmaceutical law. 3. Is 3-FPO the same as MDMA or 3-MMC? No. 3-FPO differs chemically from both MDMA (no methylenedioxy bridge; different side-chain geometry) and 3-MMC (no β-keto motif; fluorine substitution instead of methyl group). Structural similarity does not mean identity of effect. No direct pharmacological comparative data are available. 4. Why is 3-FPO referred to as a "Rita alternative"? The term circulates in online communities as a marketing label intended to suggest an MDMA-like effect. amama classifies this framing as scientifically misleading: the activity profile of 3-FPO is not established, and the safety profile differs fundamentally from that of known substances due to the structural differences and the absence of research. 3-FPO is not recommended by amama as a consumer substance or substitute for any substance. 5. What research data exist on 3-FPO? Direct peer-reviewed primary studies on 3-FPO are not retrievable in the common scientific databases (as of May 2026). The pharmacological classification is based on structural-analogy inferences from the research literature on related compounds such as 3-MMC, MDMA and fluorinated amphetamine derivatives. This underscores the need for controlled preclinical research on this substance class. 6. Who may purchase 3-FPO (Solyra) from amama? Solyra (3-FPO) is sold exclusively to adult purchasers who acquire the material for legitimate research, analytical or forensic purposes. By making a purchase, buyers confirm that they will not use the material for human consumption. Sale for consumption purposes is expressly excluded. 7. What is the phenethylamine class? The phenethylamine class is one of the most fundamental organic substance families in pharmacology and encompasses endogenous neurotransmitters (dopamine, noradrenaline, serotonin) as well as numerous synthetic compounds. The common structural feature is the phenethylamine core (phenyl ring with an ethylamino side chain). Substitutions at the ring, at the α- or β-position, or at the nitrogen generate a broad range of pharmacological profiles — from harmless dietary constituents to strongly psychoactive compounds. 8. How does 3-FPO differ chemically from MDMA and 3-MMC? MDMA carries a characteristic methylenedioxy bridge on the aromatic ring and an α-methyl substituent. 3-MMC is a cathinone derivative with a β-keto group and a 3-methyl group on the ring. 3-FPO, by contrast, carries a fluorine group at the meta-position, without the methylenedioxy bridge or the β-keto motif. These differences are pharmacologically significant and do not permit direct inferences about MDMA or 3-MMC properties. 9. Are there clinical studies with 3-FPO in humans? No. To the best of current knowledge, no registered clinical studies (Phase I–III) with 3-FPO in humans exist. This fundamentally distinguishes 3-FPO from substances such as MDMA, for which ongoing clinical studies in the context of MDMA-assisted psychotherapy research exist in the USA and Europe (MAPS studies). Without clinical studies, the human safety profile of 3-FPO is not characterised. 10. What should I bear in mind regarding shipping and storage of research chemicals? Research chemicals such as Solyra (3-FPO) should be stored in accordance with the conditions stated on the label — typically cool (2–8 °C or room temperature depending on specification), dry, protected from light and in the original sealed container. Access should be restricted to authorised research personnel. For shipping, the applicable national and international regulations for chemical substances apply. amama is available to research customers for questions regarding storage and shipping compliance. 11. Related amama Content and Collections For the scientific context of this research chemical, we refer to the following further resources in the amama network: Research chemicals collection — All analytical reference materials Legal status of new psychoactive substances in Germany 2026 — Overview Iboga & Ibogain — Scientific guide to a traditional substance Harm reduction and substance safety — amama resource centre Last updated: May 2026 | amama.space – Berlin Smartshop | Material for research, analysis and forensic purposes | All information provided without guarantee of completeness or currency of the legal position. ⚠️ For research use only, not for human consumption. This article is exclusively scientific and legal information. No application recommendation. No medical advice. No legal advice. In medical emergencies: Emergency 112. For legal questions: specialist lawyer in narcotics and pharmaceutical law. ⚠️ Designer Compounds at amama: Browse the Designer Compounds collection →

Learn more